Intraperitoneal bilirubin administration decreases infarct area in a rat coronary ischemia/reperfusion model

Frontiers in Physiology

Volumn 5 FEB, Issue , 2014, Pages

  Ben Amotz, Ron ^a   Bonagura, John ^a   Velayutham, Murugesan ^b   Hamlin, Robert ^a   Burns, Patrick ^c   Adin, Christopher ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Antioxidant; Bilirubin; Cardiac ischemia; Fractional shortening; Infarct area; Ischemia reperfusion injury; Myocardial infarction

Indexed keywords

BILIRUBIN; CARDIOLIPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; FRACTIONAL FLOW RESERVE; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LIPID OXIDATION; MALE; NONHUMAN; RAT; REPERFUSION INJURY;

EID: 84895478668     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2014.00053     Document Type: Article

References (62)

1. Adin, C. A., Croker, B. P., and Agarwal, A. (2005). Protective effects of exogenous bilirubin on ischemia-reperfusion injury in the isolated, perfused rat kidney. Am. J. Physiol. Renal Physiol. 288, F778-F784. doi: 10.1152/ajprenal.00215.2004.
2. Bolli, R. (1988). Oxygen-derived free radicals and postischemic myocardial dysfunction ("stunned myocardium"). J. Am. Coll. Cardiol. 12, 239-249. doi: 10.1016/0735-1097(88)90381-6.
3. Bolli, R. (1990). Mechanism of myocardial "stunning." Circulation 82, 723-738. doi: 10.1161/01.CIR.82.3.723.
4. Bolli, R. (1992) Myocardial "stunning" in man. Circulation 86, 1671-1691. doi: 10.1161/01.CIR.86.6.1671.
5. Bonnell, M. R., Visner, G. A., Zander, D. S., Mandalapu, S., Kazemfar, K., Spears, L., et al. (2004). Heme-oxygenase-1 expression correlates with severity of acute cellular rejection in lung transplantation. J. Am. Coll. Surg. 198, 945-952. doi: 10.1016/j.jamcollsurg.2004.01.026.
6. Breimer, L. H., Wannamethee, G., Ebrahim, S., and Shaper, A. G. (1995). Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin. Chem. 41, 1504-1508.
7. Cheng, Y., Zhu, P., Yang, J., Liu, X., Dong, S., Wang, X., et al. (2010). Ischaemic preconditioning-regulated miR-21 protects heart against ischaemia/reperfusion injury via anti-apoptosis through its target PDCD4. Cardiovasc. Res. 87,431-439. doi: 10.1093/cvr/cvq082.
8. Clark, J. E., Foresti, R., Sarathchandra, P., Kaurserum, H., Green, C. J., and Motterlini, R. (2000). Heme oxygenase-1-derived bilirubin ameliorates postischemic myocardial dysfunction. Am. J. Physiol. Heart Circ. Physiol. 278, H643-H651.
9. Dispersyn, G. D., and Borgers, M. (2001) Apoptosis in the heart: about programmed cell death and survival. News Physiol. Sci.16, 41-47.
10. Djousse, L., Levy, D., Cupples, L. A., Evans, J. C., D'Agostino, R. B., and Ellison, R. C. (2001). Total serum bilirubin and risk of cardiovascular disease in the framingham offspring study. Am. J. Cardiol. 87, 1196-1200. doi: 10.1016/S0002-9149(01)01494-1.
11. Droogmans, S., Lauwers, R., Cosyns, B., Roosens, B., Franken, P. R., Weytjens, C., et al. (2008). Impact of anesthesia on valvular function in normal rats during echocardiography. Ultrasound Med. Biol. 34, 1564-1572. doi: 10.1016/j.ultrasmedbio.2008.02.017.
12. Ferrari, R., Agnoletti, L., Comini, L., Gaia, G., Bachetti, T., Cargnoni, A., et al. (1998). Oxidative stress during myocardial ischaemia and heart failure. Eur. Heart J. 19(Suppl. B), B2-B11.
13. Fishbein, M. C., Meerbaum, S., Rit, J., Lando, U., Kanmatsuse, K., Mercier, J. C., et al. (1981). Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Am. Heart J. 101, 593-600. doi: 10.1016/0002-8703(81)90226-X.
14. Ghem, C., Sarmento-Leite, R. E., de Quadros, A. S., Rossetto, S., and Gottschall, C. A. (2010). Serum bilirubin concentration in patients with an established coronary artery disease. Int. Heart J. 51, 86-91. doi: 10.1536/ihj.51.86.
15. Gollan, J. L., Huang, S. N., Billing, B., and Sherlock, S. (1975). Prolonged survival in three brothers with severe type 2 Crigler-Najjar syndrome. Ultrastructural and metabolic studies. Gastroenterology 68, 1543-1555.
16. Gonzalvez, F., and Gottlieb, E. (2007). Cardiolipin: setting the beat of apoptosis. Apoptosis.12, 877-885. doi: 10.1007/s10495-007-0718-8.
17. Gul, M., Uyarel, H., Ergelen, M., Akgul, O., Karaca, G., Turen, S., et al. (2013). Prognostic value of total bilirubin in patients with ST-segment elevation acute myocardial infarction undergoing primary coronary intervention. Am. J. Cardiol. 111, 166-171. doi: 10.1016/j.amjcard.2012.09.011.
18. Hagar, J. M., Matthews, R., and Kloner, R. A. (1995). Quantitative two-dimensional echocardiographic assessment of regional wall motion during transient ischemia and reperfusion in the rat. J. Am. Soc. Echocardiogr. 8, 162-174. doi: 10.1016/S0894-7317(05)80405-5.
19. Hansen, T. W. (1993). Bilirubin and brain toxicity in neonates: dead but won't lie down? Pediatrics 91, 1218-1219.
20. Hopkins, P. N., Wu, L. L., Hunt, S. C., James, B. C., Vincent, G. M., and Williams, R. R. (1996). Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 16, 250-255. doi: 10.1161/01.ATV.16.2.250.
21. Jakobsen, C. J., Torp, P., Vester, A. E., Folkersen, L., Thougaard, A., and Sloth, E. (2010). Ketamine reduces left ventricular systolic and diastolic function in patients with ischaemic heart disease. Acta Anaesthesiol. Scand. 54, 1137-1144. doi: 10.1111/j.1399-6576.2010.02283.x.
22. Kapitulnik, J. (2004). Bilirubin: an endogenous product of heme degradation with both cytotoxic and cytoprotective properties. Mol. Pharmacol. 66, 773-779. doi: 10.1124/mol.104.002832.
23. Kato, Y., Shimazu, M., Kondo, M., Uchida, K., Kumamoto, Y., Wakabayashi, G., et al. (2003). Bilirubin rinse: a simple protectant against the rat liver graft injury mimicking heme oxygenase-1 preconditioning. Hepatology 38, 364-373 doi: 10.1053/jhep.2003.50300.
24. Kaur, H., Hughes, M. N., Green, C. J., Naughton, P., Foresti, R., and Motterlini, R. (2003). Interaction of bilirubin and biliverdin with reactive nitrogen species. FEBS Lett. 543, 113-119. doi: 10.1016/S0014-5793(03)00420-4.
25. Kirkby, K. A., and Adin, C. A. (2006). Products of heme oxygenase and their potential therapeutic applications. Am. J. Physiol. Renal Physiol. 290, F563-F571. doi: 10.1152/ajprenal.00220.2005.
26. Kirkby, K., Baylis, C., Agarwal, A., Croker, B., Archer, L., and Adin, C. (2007). Intravenous bilirubin provides incomplete protection against renal ischemia-reperfusion injury in vivo. Am. J. Physiol. Renal Physiol. 292, F888-F894. doi: 10.1152/ajprenal.00064.2006.
27. Kluck, R. M., Bossy-Wetzel, E., Green, D. R., and Newmeyer, D. D. (1997). The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275, 1132-1136. doi: 10.1126/science.275.5303.1132.
28. Lanone, S., Bloc, S., Foresti, R., Almolki, A., Taillé, C., Callebert, J., et al. (2005). Bilirubin decreases NOS2 expression via inhibition of NAD(P)H oxidase: implications for protection against endotoxic shock in rats. FASEB J. 19, 1890-1892. doi: 10.1096/fj.04-2368fje.
29. Laws, H. F. 2nd. (1978). Toxicity of bilirubin in the neonates. J. Pediatr. 92, 858. doi: 10.1016/S0022-3476(78)80189-9.
30. Maines, M. D. (1988). Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J. 2, 2557-2568.
31. Masini, E., Vannacci, A., Marzocca, C., Pierpaoli, S., Giannini, L., Fantappié, O., et al. (2003). Heme oxygenase-1 and the ischemia-reperfusion injury in the rat heart. Exp. Biol. Med. 228, 546-549.
32. Mayer, M. (2000). Association of serum bilirubin concentration with risk of coronary artery disease. Clin. Chem. 46, 1723-1727.
33. Melo, L. G., Agrawal, R., Zhang, L., Rezvani, M., Mangi, A. A., Ehsan, A., et al. (2002). Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. Circulation 105, 602-607. doi: 10.1161/hc0502.103363.
34. Minetti, M., Mallozzi, C., Di Stasi, A. M., and Pietraforte, D. (1998). Bilirubin is an effective antioxidant of peroxynitrite-mediated protein oxidation in human blood plasma. Arch. Biochem. Biophys. 352, 165-174. doi: 10.1006/abbi.1998.0584.
35. Nakao, A., Choi, A. M., and Murase, N. (2006). Protective effect of carbon monoxide in transplantation. J. Cell. Mol. Med. 10, 650-671. doi: 10.1111/j.1582-4934.2006.tb00426.x.
36. Nakao, A., Kimizuka, K., Stolz, D. B., Seda, N. J., Kaizu, T., Choi, AM., et al. (2003). Protective effect of carbon monoxide inhalation for cold-preserved small intestinal grafts. Surgery 134, 285-292 doi: 10.1067/msy.2003.238.
37. Nakao, A., Neto, J. S., Kanno, S., Stolz, D. B., Kimizuka, K., Liu, F., et al. (2005). Protection against ischemia/reperfusion injury in cardiac and renal transplantation with carbon monoxide, biliverdin and both. Am. J. Transplant. 5, 282-291 doi: 10.1111/j.1600-6143.2004.00695.x.
38. Novotnỳ, L., and Vítek, L. (2003). Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp. Biol. Med. 228, 568-571.
39. Ollinger, R., Bilban, M., Erat, A., Frolo, A., McDaid, J., Tyagi, S., et al. (2005). Bilirubin: a natural inhibitor of vascular smooth muscle cell proliferation. Circulation 112, 1030-1039. doi: 10.1161/CIRCULATIONAHA.104.528802.
40. Ollinger, R., Yamashita, K., Bilban, M., Erat, A., Kogler, P., Thomas, M., et al. (2007). Bilirubin and biliverdin treatment of atherosclerotic diseases. Cell Cycle 6, 39-43. doi: 10.4161/cc.6.1.3700.
41. Orrenius, S., and Zhivotovsky, B. (2005). Cardiolipin oxidation sets cytochrome c free. Nat. Chem. Biol. 1, 188-189. doi: 10.1038/nchembio0905-188.
42. Plante, E., Lachance, D., Roussel, E., Drolet, M. C., Arsenault, M., and Couet, J. (2006). Impact of anesthesia on echocardiographic evaluation of systolic and diastolic function in rats. J. Am. Soc. Echocardiogr. 19, 1520-1525. doi: 10.1016/j.echo.2006.06.011.
43. Scheidt, P. C., Mellits, E. D., Hardy, J. B., Drage, J. S., and Boggs, T. R. (1977). Toxicity to bilirubin in neonates: infant development during first year in relation to maximum neonatal serum bilirubin concentration. J. Pediatr. 91, 292-297. doi: 10.1016/S0022-3476(77)80835-4.
44. Schwertner, H. A., Jackson, W. G., and Tolan, G. (1994). Association of low concentration of bilirubin with increased risk of coronary artery disease. Clin. Chem. 40, 18-23.
45. Sedlak, T. W., Saleh, M., Higginson, D. S., Paul, B. D., Juluri, K. R., and Snyder, S. H. (2009). Bilirubin and glutathione have complementary antioxidant and cytoprotective roles. Proc. Natl. Acad. Sci. U.S.A. 106, 5171-5176. doi: 10.1073/pnas.0813132106.
46. Sedlak, T. W., and Snyder, S. H. (2004). Bilirubin benefits: cellular protection by a biliverdin reductase antioxidant cycle. Pediatrics 113, 1776-1782. doi: 10.1542/peds.113.6.1776.
47. Sies, H., and Stahl, W. (1995). Vitamins E and C, beta-carotene, and other carotenoids as antioxidants. Am. J. Clin. Nutr. 62(Suppl. 6), 1315S-1321S.
48. Stein, A. B., Tiwari, S., Thomas, P., Hunt, G., Levent, C., Stoddard, M. F., et al. (2007). Effects of anesthesia on echocardiographic assessment of left ventricular structure and function in rats. Basic Res. Cardiol. 102, 28-41. doi: 10.1007/s00395-006-0627-y.
49. Stocker, R., Yamamoto, Y., McDonagh, A. F., Glazer, A. N., and Ames, B. N. (1987). Bilirubin is an antioxidant of possible physiological importance. Science 235, 1043-1046. doi: 10.1126/science.3029864.
50. Temme, E. H., Zhang, J., Schouten, E. G., and Kesteloot, H. (2001). Serum bilirubin and 10-year mortality risk in a belgian population. Cancer Causes Control 12, 887-894. doi: 10.1023/A:1013794407325.
51. Tomaselli, G. F., and Barth, A. S. (2010). Sudden cardio arrest: oxidative stress irritates the heart. Nat. Med. 16, 648-649. doi: 10.1038/nm0610-648.
52. Tullius, S. G., Nieminen-Kelha, M., Buelow, R., Reutzel-Selke, A., Martins, P. N., Pratschke, J., et al. (2002). Inhibition of ischemia/reperfusion injury and chronic graft deterioration by a single-donor treatment with cobalt-protoporphyrin for the induction of heme oxygenase-1. Transplantation 74, 591-598. doi: 10.1097/00007890-200209150-00001.
53. Velayutham, M., Hemann, C., and Zweier, J. L. (2011). Removal of H2O2 and generation of superoxide radical: role of cytochrome c and NADH. Free Radic. Biol. Med. 51, 160-170. doi: 10.1016/j.freeradbiomed.2011.04.007.
54. Vitek, L., and Ostrow, J. D. (2009). Bilirubin chemistry and metabolism; harmful and protective aspects. Curr. Pharm. Des. 15, 2869-2883. doi: 10.2174/138161209789058237.
55. Vulapalli, S. R., Chen, Z., Chua, B. H., Wang, T., and Liang, C. S. (2002). Cardioselective overexpression of HO-1 prevents I/R-induced cardiac dysfunction and apoptosis. Am. J. Physiol. Heart Circ. Physiol. 283, H688-H694.
56. Wang, H., Lee, S. S., Dell'Agnello, C., Tchipashvili, V., d'Avila, J. C., Czismadia, E., et al. (2006). Bilirubin can induce tolerance to islet allografts. Endocrinology 147, 762-768. doi: 10.1210/en.2005-0632.
57. Wang, W. W., Smith, D. L. H., and Zucker, S. D. (2004). Bilirubin inhibits iNOS expression and NO production in response to endotoxin in rats. Hepatology 40, 424-433. doi: 10.1002/hep.20334.
58. Werns, S. W., Shea, M. J., and Lucchesi, B. R. (1985). Free radicals in ischemic myocardial injury. J. Free Radic. Biol. Med. 1, 103-110. doi: 10.1016/0748-5514(85)90013-3.
59. Werns, S. W., Shea, M. J., and Lucchesi, B. R. (1986). Free radicals and myocardial injury: pharmacologic implications. Circulation 74, 1-5. doi: 10.1161/01.CIR.74.1.1.
60. Yet, S. F., Tian, R., Layne, M. D., Wang, Z. Y., Maemura, K., Solovyeva, M., et al. (2001). Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice. Circ. Res. 89, 168-173. doi: 10.1161/hh1401.093314.
61. Ytrehus, K., Liu, Y., Tsuchida, A., Miura, T., Liu, G. S., Yang, X. M., et al. (1994). Rat and rabbit heart infarction: effects of anesthesia, perfusate, risk zone, and method of infarct sizing. Am. J. Physiol. 267, H2383-H2390.
62. Zweier, J. L., and Talukder, M. A. (2006). The role of oxidants and free radicals in reperfusion injury. Cardiovasc. Res. 70, 181-190. doi: 10.1016/j.cardiores.2006.02.025.